Status:

WITHDRAWN

HepQuant to Predict Hepatic Encephalopathy After TIPS

Lead Sponsor:

Northwestern University

Collaborating Sponsors:

HepQuant, LLC

Conditions:

Hepatic Encephalopathy

Cirrhosis, Liver

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

A pilot study to determine if a simple blood test can predict patients at risk for significant episodes of confusion and disorientation that can occur in patients who receive an artificial shunt throu...

Eligibility Criteria

Inclusion

  • Subjects over the age of 18 able to provide consent
  • Subjects undergoing initial TIPS procedure for the primary indication of treatment of ascites

Exclusion

  • Prisoners
  • Pregnant women
  • Subjects undergoing TIPS placement as part of an investigational study outside of usual clinical care
  • Subjects taking beta-blocker medications or angiotensin converting enzyme inhibitors
  • Subjects with evidence of porto-systemic shunts present on imaging (eg splenorenal shunt)
  • Subjects with calculated MELD score \>12 based on most recent laboratory values before consent
  • Subjects with prior history of overt hepatic encephalopathy (grade 3-4) that was primary reason for hospitalization. Episodes of hepatic encephalopathy that were the consequence of other precipitating event (such as variceal bleeding or infection) will not be considered exclusionary.
  • Subjects with a known sensitivity to albumin preparations, any ingredient in the formulation, or components of the container
  • Subjects unable to fast for \>5 hours prior to the HepQuant administration or subjects who are unable to drink the oral dose of the cholate (\~40mL of liquid).

Key Trial Info

Start Date :

February 25 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 30 2021

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT04664621

Start Date

February 25 2020

End Date

September 30 2021

Last Update

August 9 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Northwestern University

Chicago, Illinois, United States, 60611